Factors Affecting the Pharmacology of Antibody–Drug Conjugates
AbstractMajor advances in therapeutic proteins, including antibody–drug conjugates (ADCs), have created revolutionary drug delivery systems in cancer over the past decade. While these immunoconjugate agents provide several advantages compared to their small-molecule counterparts, their clinical use is still in its infancy. The considerations in their development and clinical use are complex, and consist of multiple components and variables that can affect the pharmacologic characteristics. It is critical to understand the mechanisms employed by ADCs in navigating biological barriers and how these factors affect their biodistribution, delivery to tumors, efficacy, and toxicity. Thus, future studies are warranted to better understand the complex pharmacology and interaction between ADC carriers and biological systems, such as the mononuclear phagocyte system (MPS) and tumor microenvironment. This review provides an overview of factors that affect the pharmacologic profiles of ADC therapies that are currently in clinical use and development. View Full-Text
Share & Cite This Article
Lucas, A.T.; Price, L.S.L.; Schorzman, A.N.; Storrie, M.; Piscitelli, J.A.; Razo, J.; Zamboni, W.C. Factors Affecting the Pharmacology of Antibody–Drug Conjugates. Antibodies 2018, 7, 10.
Lucas AT, Price LSL, Schorzman AN, Storrie M, Piscitelli JA, Razo J, Zamboni WC. Factors Affecting the Pharmacology of Antibody–Drug Conjugates. Antibodies. 2018; 7(1):10.Chicago/Turabian Style
Lucas, Andrew T.; Price, Lauren S.L.; Schorzman, Allison N.; Storrie, Mallory; Piscitelli, Joseph A.; Razo, Juan; Zamboni, William C. 2018. "Factors Affecting the Pharmacology of Antibody–Drug Conjugates." Antibodies 7, no. 1: 10.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.